Wednesday, April 3, 2013

Western Drugmakers Expected To Practice Caution After Patent Defeat In India.

Reuters (4/3, Hirschler, Kulkarni) reports on Western drugmakers' reaction to a landmark patent defeat in India. Amit Backliwal, who heads South Asian operations for IMS Health, remarked, "India is too big to ignore. Companies will definitely get cautious, and it definitely means a change in their business model, but I don't think they will pull out." Raghunath Mashelkar, former director general of the Council for Scientific and Industrial Research and an architect of India's IP policies, added, "Drugmakers will have to work out strategies for the lower sections, to give affordable access to medicines and make money by large volumes and smaller margins. And then they will look at the middle and the upper sections and make money through smaller volumes but higher margins."
US Business Reacts To Ruling.Reuters (4/3, Palmer) reports that the US Trade Representative's office is considering its response to the ruling, while the US-India Business Council and other business groups have criticized it.
 
DIA Daily. This daily enewsletter features summaries of breaking news and information about the pharmaceutical, biotechnology, and medical device fields from thousands of global news sources. This easy-to-read enewsletter is delivered to your inbox every business morning.
Subscribe to the DIA Daily.View archives.
iPhone and iPad Apps available!
Download "BulletinHC."DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.

If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email membership@diahome.org.Click here to check your membership status.

Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191

Other related links:

Business Standard
Even though Novartis and other multinational corporations (MNCs) are upset with the Indian Supreme Court's decision to reject Novartis' patent claim on Glivec, the key man behind the popular cancer drug has welcomed the verdict, saying it would benefit ...
 
 
The Hindu
A day after losing in the Supreme Court its seven-year battle over patent protection for anti-cancer drug, Glivec, Novartis India's Vice Chairman and Managing Director, Ranjit Shahani, said that destroying the patent model is not the solution to make medicines ...
 
Hindu Business Line
“No way will drug companies move out of India because of Supreme Court ruling against Novartis. They need our (Indian) market and (they) will find ways to sell drug cheaper,” tweeted internationally-reputed filmmaker Shekhar Kapoor, reacting to the ...
 

Hindustan Times

The Supreme Court's (SC's) verdict on Swiss multinational Novartis AG's blockbuster anti-cancer drug, Glivec, is almost a classic East versus West story and it seems never the twain shall meet over the contentious issues of drug pricing and patenting rules.
  

Firstpost

Yesterday's Supreme Court judgment in the case of Novartis' anti-cancer drug Glivec has given rise to calls for stronger patent protection in India. The multinational lobby is yelling blue murder, and Novartis India's chief Ranjit Shahani has muttered darkly ...
  
India's Cancer-Drug Ruling Likely to Have Global Impact
Voice of America - ‎12 hours ago‎

A landmark ruling by India's high court this week struck down a bid by Swiss drugmaker Novartis to extend patent protection for its cancer drug, Glivec. The decision is seen as a blow to Western pharmaceutical companies seeking to protect their financial ...
  

Bloomberg

Novartis AG feels stung by the Indian Supreme Court's decision this week to deny patent protection to the company's Gleevec cancer treatment. Its spokesmen have gone so far as to threaten to withhold investments and even products from the country.
  

Reuters India

By Doug Palmer. WASHINGTON | Wed Apr 3, 2013 5:19am IST. WASHINGTON (Reuters) - The United States said on Tuesday it was considering its response to the Supreme Court ruling that U.S. drug manufacturers warn is the latest sign of a "deteriorating" ...


6th Regulatory Conference | NEW DATE! May 23-24, 2013 | Ahmedabad, India
Book Now to Enjoy Insightful Sessions in May
Dear Colleagues,
Due to unavoidable circumstances we will be postponing the 6th Regulatory Conference in India. The conference will now be held on Thursday 23rd and Friday 24th May at the Courtyard Marriott in Ahmedabad, Gujarat.
It is DIA’s constant endeavor to bring to you world class programs with renowned speakers. We hope you can join us at the conference in May.
Seats are still available for the event. Please take a look at the conference program to find the sessions that interest you and register today.
Best regards,
DIA India
Conference on Technological Advances in Meeting Regulatory Challenges
Email Preferences | My DIA | Forward to a Friend | Facebook LinkedIn Twitter YouTube Flickr

DIANews & PublicationsMeetings & TrainingsSpeaking & PublishingNetworking & CommunitiesExhibiting AdvertisingCareer Center
 
 

No comments:

Post a Comment